This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy Study of the DIAMOND System to Treat Type 2 Diabetes Mellitus (RUBY)

This study has been completed.
Information provided by (Responsible Party):
Metacure Identifier:
First received: January 31, 2012
Last updated: March 15, 2016
Last verified: March 2016

The study purpose is to demonstrate the benefit of a simplified version of the DIAMOND System (A third Generation) in comparison to a sham treatment in terms of Glycemic control, measured as A1c, FBG and Post-Prandial Glucose levels.

The study hypothesis is that HbA1c will show greater improvement in patients receiving 12 months of therapy by the DIAMOMD System than in patients not receiving this therapy.

Condition Intervention
Type 2 Diabetes Mellitus Device: DIAMOND System

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: An Advanced Configuration (The Third Generation) of the DIAMOND System for the Treatment of T2DM Patients - A Randomized, Double Blind Study

Further study details as provided by Metacure:

Primary Outcome Measures:
  • HbA1c [ Time Frame: 12 months ]
    The primary end point will be the difference, at 12 months, in HbA1c change from baseline, between the pts treated with the active signal compared to patients treated with a Sham System.

Secondary Outcome Measures:
  • HbA1c [ Time Frame: 6 months ]
    The difference, at 6 months in HbA1c change from baseline, between the pts treated with the active signal compared to patients treated with a Sham System.

  • GI hormones (C-peptide, Glucagon, Ghrelin, GLP-1, PYY, Gastrin and Somatostatin) [ Time Frame: 6 and 12 months ]
    To detect differences in the pattern of meal-related release of GI hormones (slope / area under the curve, etc)between the treatment and the control groups, as analyzed by repeated-measures ANOVA. Glucose, insulin and the following GI hormones will be measured prior and post meal consumption: C-peptide, Glucagon, Ghrelin, GLP-1, PYY, Gastrin and Somatostatin.

  • Metabolic parameters (fasting and post Prandial glucose, blood pressure, lipids and cholesterol, weight and waist circumference) [ Time Frame: 6 and 12 months ]
    The difference in metabolic parameters at 6 and 12 months from baseline between the two arms. Including: fasting and post Prandial glucose, blood pressure, lipids and cholesterol, weight and waist circumference.

  • Triglycerides [ Time Frame: Baseline ]
    The effect of the TG level at baseline on treatment efficacy

  • HbA1c [ Time Frame: 24 months ]
    The change in HbA1c from baseline to 12 months and 24 months

Enrollment: 2
Study Start Date: May 2012
Study Completion Date: January 2015
Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Electrical signal ON
Subjects randomized to this group (Group A) will receive electrical stimulation delivered to the fundus for 24 months.
Device: DIAMOND System
Electrical stimulation to the fundus
Sham Comparator: Sham
Subjects randomized to this group (Group B) will have their device in "turned off" mode for the first 12 months (48 weeks) after implant. Then the device will be turned ON and these subjects will receive therapy for the remaining 12 months of the study.
Device: DIAMOND System
Electrical stimulation to the fundus

Detailed Description:
The study protocol will also apply measures to better understand the mechanism of action of the effect.

Ages Eligible for Study:   21 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female subjects 21 through 70 years of age
  • Body mass index ≥28 and ≤ 45 (kg/m2)
  • Type 2 diabetes duration more than 6 months and less than 10 years.
  • A baseline measurement (visit BL1) of HbA1c between ≥ 7.5% and ≤ 10.5%,
  • Type 2 diabetic subjects treated for at least 3 months with one or more maximum tolerable dosage of anti-diabetic agent (Any of the following: Sulfonylurea, Metformin, thiazolinedione (TZD), DPP-4 inhibitors).
  • Stable anti-hypertensive and lipid-lowering medication for at least one month prior to enrollment, if taken
  • Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods
  • Ability and willingness to perform required study and data collection procedures and adhere to operating requirements of the System
  • Alert, mentally competent, and able to understand and willing to comply with the requirements of the clinical trial, and personally motivated to abide by the requirements and restrictions of the clinical trial
  • Able to provide voluntary informed consent

Exclusion Criteria:

  • Injectable anti-diabetic therapy within the last 3 months (such as insulin and/or GLP-1 receptor agonists)
  • Taking medications known to affect gastric motility such as narcotics (chronic use) and anticholinergics/antispasmodics
  • Any gastric or upper GI surgery
  • Experiencing severe and progressing diabetic complications (i.e. retinopathy not stabilized, nephropathy with macroalbuminuria)
  • Prior wound healing problems
  • Diagnosed with past or current psychiatric condition that may impair his or her ability to comply with the study procedures
  • Use of anti-psychotic medications
  • Diagnosed with an eating disorder such as bulimia or binge eating
  • Obesity due to an endocrinopathy (e.g. Cushing disease, Hypothyroidism not treated)
  • Hiatal hernia requiring surgical repair or a paraesophageal hernia
  • Pregnant or lactating
  • Diagnosed with impaired liver function (liver enzymes 3 times greater than normal)
  • Any prior bariatric surgery
  • Any history of pancreatitis
  • Any history of peptic ulcer disease within 10 years of enrollment
  • Diagnosed with Gastroparesis or other GI motility disorder
  • Use of active medical devices (either implantable or external) such as ICD, pacemaker, drug infusion device, or neurostimulator (either implanted or worn). Subjects using an external active device who are able and willing to avoid use of the device during the study may be enrolled.
  • Cardiac history that physician /surgeon feels should exclude the subject from the study.
  • Use of another investigational device or agent in the 30 days prior to enrollment
  • A history of life-threatening disease within 5 years of enrollment
  • Any additional condition(s) that in the Investigator‟s opinion would warrant exclusion from the study or prevent the subject from completing the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01529216

Hospital Georges Pompidou
Paris, France
Atrium Medisch Centrum
Heerlen, Netherlands
Sponsors and Collaborators
Principal Investigator: Jan W.M. Greve, MD Atrium medisch centrum METC, Heerlen, The Netherlands
Principal Investigator: Chevallier, MD Hôpital GEORGES POMPIDOU 20 Rue Leblanc 75015 Paris, France
  More Information

Additional Information:
Responsible Party: Metacure Identifier: NCT01529216     History of Changes
Other Study ID Numbers: MC CP TAN2011- 014
Study First Received: January 31, 2012
Last Updated: March 15, 2016

Keywords provided by Metacure:
Randomized study
Electrical stimulation

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases processed this record on September 19, 2017